

BioScrip, Inc.
Form 8-K
July 09, 2013

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): July 9, 2013

BIOSCRIP, INC.

(Exact name of Registrant as specified in its charter)

Delaware 000-28740 05-0489664

(State of Incorporation) (Commission File Number) (I.R.S. Employer
Identification No.)

100 Clearbrook Road, Elmsford, New York 10523

Edgar Filing: BioScrip, Inc. - Form 8-K

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (914) 460-1600

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 – Other Events.

On July 9, 2013, BioScrip, Inc. (“BioScrip”) issued a press release announcing that it extended the consent payment deadline, the withdrawal deadline and the expiration date to 5:00 p.m. New York City time on July 30, 2013 with respect to its previously announced cash tender offer and consent solicitation for any and all of its \$225 million aggregate principal amount of 10¼ % Senior Notes dues 2015 (the “Notes”). The Company also announced that, as of the close of business on July 8, 2013, the consent of approximately \$104.4 million or 46.38% in aggregate principal amount of the outstanding Notes have been received. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01 – Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number Description

99.1 Press Release dated July 9, 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOSCRIP, INC.

Date: July 9, 2013 By: /s/ Kimberlee C. Seah
Kimberlee C. Seah

Senior Vice President and General Counsel

Index to Exhibits

Exhibit Number Description

99.1 Press Release dated July 9, 2013.